The global sales of prostate cancer are estimated to be worth USD 12.9 billion in 2025 and anticipated to reach a value of USD 29.2 billion by 2035. Sales are projected to rise at a CAGR of 8.5% over the forecast period between 2025 and 2035. The revenue generated by prostate cancer in 2024 was USD 11.9 billion.
Greater incidence of prostate cancer is the leading factor among factors impacting world growth in the prostate cancer market. There are two problems behind the trend: aging and greater disease awareness. Prostate cancer is one of the most common types of cancer detected in men; as men live longer, the morbidity keeps on growing.
As per World Health Organization, prostate cancer is one of the top oncological killers among men, especially those parts of North America, Europe and part of Asia that are older populations. According to the American Cancer Society in 2024 every eight men will have prostate cancer; incidence and mortality of this disease are expected to be 299,010 and 35,250, respectively.
Prostate cancer is the second-most common cancer among men, with an estimated 1.4 million new cases and 375,000 deaths in 2020. And it has doubled, with 1.47 million new cases in 2022, becoming the fourth-most prevalent cancer on the planet. This increasing incidence isn’t because of an aging population but better awareness that leads to more diagnoses.
Global Prostate Cancer Industry Analysis
| Attributes | Key Insights |
|---|---|
| Industry Size (2025E) | USD 12.9 billion |
| Industry Value (2035F) | USD 29.2 billion |
| CAGR (2025 to 2035) | 8.5% |
The aging process is a major risk factor; as prostate cancer is more prevalent in older men. As life expectancy increases all around the globe, the population is shifting toward having more men aged 65 years old and beyond - increased propensity to this disease, thus raising the number of diagnosed prostate cancers. Lifestyle factors such as unhealthy diets, physical inactivity, and increased obesity levels have also been associated with an increased risk of prostate cancer.
This increasing trend has also made it increasingly essential to seek earlier diagnostic aids like PSA testing and newer imaging techniques, including multiparametric MRI. Detection early has also taken the front seat in ensuring the possibility of better treatment intervention for the improvement of survival chances. Also, this patient population has accelerated research into more novel therapies such as targeted therapy, immunotherapy, and radiopharmaceuticals.
Health awareness programs and government campaigns for routine prostate cancer screening have contributed significantly towards increasing diagnosis rates. The increase in global burden on prostate cancer is expected to open more and additional market opportunities, which are projected to fuel market growth through improved diagnostics and treatments as well as enhanced healthcare services.
Explore FMI!
Book a free demo
The below table presents the expected CAGR for the global market over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 9.5%, followed by a slightly lower growth rate of 9.1% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 9.5% (2024 to 2034) |
| H2 | 9.1% (2024 to 2034) |
| H1 | 8.5% (2025 to 2035) |
| H2 | 8.2% (2025 to 2035) |
From there, growth continues for the next period, and H1 2025 to H2 2035 sees the CAGR remain at a lesser 8.5% in the first half and a moderately slower 8.2% in the second half. S&M growth H1 = 100 BPS vs H2 = −90 BPS
Expansion of Immunotherapy Options is a Transformative Driver for Prostate Cancer
Immunotherapy development has been the more revolutionary force in the field of prostate cancer treatments. These methods work by using the body's immune system as a medium in the recognition and killing of tumors. Long-term responses in traditional therapies often offer less than optimal toleration of these newer methods, which is much favorable to the clinician and the patient.
The application of immune checkpoint inhibitors, including pembrolizumab, are the most prominent advancements in this area. They inhibit proteins like PD-1/PD-L1 hijacked by cancer cells to evade immune recognition.
Checkpoint inhibitors have been only marginally successful to date in prostate cancer because of its "cold tumor" nature, but ongoing studies are examining its application with other therapies, including androgen receptor inhibitors and radiotherapy, to enhance response rates.
A further exciting example involves therapeutic cancer vaccines, as was first demonstrated by the FDA approval of sipuleucel-T for treating metastatic castration-resistant prostate cancer. Provenge acts via the induction of an immune response against the antigen-prostate-specific antigen, extending the life of patients where their treatment options are seriously limited.
Emergent therapies within this space currently include bispecific T-cell engagers-AMG 160-and PSMA-targeted CAR-T-cell therapies. Novel approaches have gained momentum in the clinic and even more fully rounded the immunotherapy landscape.
Rapid research and breakthroughs in the clinical arena spur investment, innovation, and steer the market in its new dawn for targeted, effective treatment.
Radiopharmaceutical Therapies Transforming Prostate Cancer Treatment Options
Radiopharmaceutical treatments use radioactive isotopes linked to molecules that selectively target cancer cells, and provide specificity and therapeutic activity. In mCRPC, which is usually chemo- or hormone-resistant in origin, they offer a highly targeted treatment and low systemic side effects.
One of these is Lutetium-177-PSMA (Pluvicto), a FDA-approved radioligand therapy for mCRPC. The therapy targets PSMA, highly expressed on prostate cancer cells, and carries the radiation directly to the tumor bed, sparing all other tissues. Significant improvements in overall survival and progression-free survival were demonstrated through the VISION study, so this has really picked up quite fast in practice.
Further boosting this niche segment are ongoing clinical trials into next-generation radiopharmaceuticals, including Actinium-225-PSMA and novel alpha-emitting agents, which demonstrate promise for higher efficacy. The growth of the market is being further boosted by favorable regulatory environments, such as expedited approvals and strong endorsements from healthcare agencies.
As healthcare systems around the world look to precision oncology, radiopharmaceuticals are gaining ground- addressing critical, unmet needs in prostate cancer and significantly broadening therapeutic choices in this emergent market.
Advancements in Biomarker Discovery Present a Significant Market Opportunity for The Prostate Cancer Landscape.
Biomarkers are measured indicators of disease presence or development. They significantly contribute to detection at an early stage, differentiated treatment, and monitoring of changes in response to therapy. Progress in prostate cancer research is enhancing the discovery of new biomarkers, which continue to change its diagnosis, therapy, and monitoring, thus proving to be more innovative and yielding opportunities for a growth market in the future.
Biomarkers discovered in recent times, which include Prostate-Specific Antigen (PSA), PCA3, ERG gene fusion, and BRCA mutations, already facilitate earlier detection and prognosis. Future research studies are aiming to detect more specific biomarkers that may predict treatment success, monitor disease progression, and even identify patients with an increased likelihood of developing aggressive forms of the disease. This has led to the growing demand for diagnostic tools and genetic testing platforms.
Other related developments in liquid biopsy technology to detect tumor-derived genetic material from blood samples, in the field of non-invasive prostate cancer detection and the monitoring of therapeutic efficacy, further grow this market opportunity with advances in next-generation sequencing and molecular profiling technologies.
Biomarker-driven drug development is another emerging direction for pharmaceutical companies. Drugs developed around specific genetic mutations or molecular markers have a possibility of more efficient action with less side effect; this fact can be the prime reason to invest in the search for biomarkers. Along these lines, rapid growth in the prostate cancer market can be foreseen in future by the pace of personalized medicine and enhanced diagnosis techniques.
Lack of Screenings and Delayed Diagnostics Pose a Significant Barrier for Market Expansion
The primary restraint in the market is the lack of full-scale screenings and delayed diagnostics. Prostate cancer is often asymptomatic at its early stages and tends to be diagnosed more severely when symptoms are noticeable. It would thus reduce the effectiveness of any available treatments but would require greater use of healthcare facilities and subsequently higher healthcare costs.
This lack of standardized screening practices contributes significantly to late diagnoses. Since the most frequently used screening test is PSA, and it works unevenly-while sometimes reporting a false positive or negative-PSA screening has led several regulatory agencies to come up with different recommendations.
According to research published by the National Cancer Institute in 2023, only 37.1% of men aged 55-69 years had a PSA test in 2021, indicating a significant gap in prostate cancer screening practices. The study highlights that since the introduction of widespread PSA testing in the USA in 1992, prostate cancer-specific mortality has decreased by over 50%; however, if all PSA screenings were suspended, an estimated 25,000 to 30,000 men would die annually from prostate cancer that could have otherwise been treated effectively within ten years
These delays result in missed opportunities for early-stage intervention, leading to more aggressive treatment regimens and poorer patient outcomes, ultimately restraining the market growth for prostate cancer diagnostics and therapies.
The global prostate cancer industry recorded a CAGR of 6.4% during the historical period between 2020 and 2024. In the 2024 financial year, the prostate cancer industry recorded a positive growth as it increased in value from USD 8.8 billion in 2020 to USD 11.9 billion.
The market has significantly improved and developed from traditional forms of therapy to the more modern and individually tailored approaches. For this, the adoption of Prostate-Specific Antigen (PSA) testing played a central role in early detection, increasing thereby treatment demand regarding radiotherapy and hormone therapy. However, false positives in PSA testing and the progression of the disease to late stages mean the race for very accurate and innovative methods of diagnosis is on.
Looking ahead, emerging treatment modalities such as immunotherapies (in particular, immune checkpoint inhibitors and cancer vaccines), radiopharmaceutical therapies (Lutetium-177-PSMA) will increasingly impact the space for metastatic prostate cancer; such therapies shall increasingly be essential for the care of advanced, CRPC patient populations, an encouraging development for most of these patient groups.
Another key trend includes the discovery of biomarkers and liquid biopsy to detect cancer early and monitor the treatment. Since prostate cancer is increasingly being understood at the molecular level, the treatment is bound to be revamped with precision medicine that will make care more effective and personalized. Another factor is going to be efforts to standardize screening guidelines around the world and increase access to healthcare in areas that have lacked it so far.
Tier 1 firms are leaders with a substantial market share of 26.1% of international market. They spend heavily on research and development to develop new treatments, particularly in point of care diagnostics and test accuracy.
Tier 1 firms also spend on strategic partnerships and acquisitions to expand their product offerings and access pioneering technologies. Additionally, they are overemphasizing-big clinical trials to validate the efficacy and safety of their drugs. High-profile tier 1 players include Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company and Pfizer Inc.
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 33.5% market share. They typically pursue partnerships with academic institutions and research organizations to leverage emerging technologies and expedite product development.
These companies often emphasize agility and adaptability, allowing them to quickly bring new treatments to market, sometimes targeting specific types of cancer or rare conditions. Second, they emphasize budget-friendly production procedures in order to provide competitive rates. Key operators at tier 2 are Ipsen Pharma, Ferring Pharmaceuticals Inc. and GlaxoSmithKline Plc
Lastly, Tier 3 firms, including Exelixis, Inc. and Clovis Oncology, Inc. They deal with specialized products and serve niche segments, diversifying the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the prostate cancer sales remains dynamic and competitive.
The section below covers the industry analysis for the market for prostate cancer for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and MEA, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In Asia Pacific, India is projected to witness a CAGR of 7.9% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 4.8% |
| Germany | 5.9% |
| France | 4.5% |
| Spain | 5.2% |
| China | 7.4% |
| India | 7.9% |
| Australia & New Zealand | 5.8% |
| South Korea | 6.3% |
United States market for prostate cancer is expected to show a CAGR of 4.8% from 2025 through 2035. It has the largest market share in the North American market at present, and such is likely to be the trend throughout the forecast period.
The United States remains among the leading countries on the globe when it comes to prostate cancer research and clinical trials that are very instrumental in driving the prostate cancer therapy market.
Major pharmaceutical companies, such as well-known research institutions and hospitals like the National Cancer Institute, spearhead significant studies. The United States has hearty funding for medical research, thereby constantly making progress on immunotherapy, precision medicine, and targeted treatments for prostate cancer.
These innovations have brought about new therapies that have proved to be more effective for patients. The USA has clinical trials not only to test new formulations of drugs but also to find out combination therapies that can lead to faster implementation of the latest treatments.
The research efforts focus on personalized care and aim to enhance patient outcomes, improve treatment efficacy, and offer tailored options for prostate cancer patients. This continuous innovation through research and clinical trials contributes positively to the growing market, where the United States remains a haven for prostate cancer therapy development.
United Kingdom market for prostate cancer is going to show a CAGR of 5.2% from 2025 to 2035. It currently has the largest share in the Western Europe market, and the same trend is expected to follow over the forecast period.
The National Health Service within the United Kingdom is a highly significant force that drives the market through providing access to universal healthcare. With the NHS, prostate cancer screening, diagnosis, and treatment are available to residents. Thus, no patient is left behind.
The wide-ranging services provided by the NHS include Prostate-Specific Antigen (PSA) testing, among other early diagnostic procedures. These early detection processes ensure timely detection of prostate cancer, thereby enabling better prognosis and more effective treatment options. In general, improved patient outcomes depend on early detection, which facilitates more targeted and less invasive treatments.
In addition, the NHS provides prostate cancer patients with the latest therapies and care plans, from advanced diagnostics to personalized treatment regimens. This system of universal healthcare and early detection creates a significant market demand for prostate cancer services, making the NHS a key driver of market growth in the United Kingdom.
India's prostate cancer market is expected to grow at a CAGR of 7.9% from 2025 to 2035. It currently has the largest share in the South Asia & Pacific market, and the trend is likely to continue throughout the forecast period.
Prostate cancer is on the rise in India. The reasons behind this are because of an aging population, increased lifestyles, and improvements in the detection of disease. As the number of old people has gone up, naturally there is an increased chance of prostate cancer as the disease affects more older men. Unhealthy eating habits, no exercise, and increased urbanization that have raised the cancer cases are the other reasons.
Thus, enhanced awareness and superior diagnostic facilities, coupled with advances in medical technologies, translate into more regular detection of prostate cancer in the early stages. This increasing diagnosis is providing an added boost to prostate-specific antigen PSA testing and follow-up treatments such as radiotherapy, hormone therapy, and chemotherapy.
Thus, the rising number of cases of prostate cancer in India would require increasing diagnostics services, treatment interventions, and healthcare infrastructure facilities. Hence, it is an important market opportunity for prostate cancer care.
The section contains information about the leading segments in the industry. By drug class, the hormonal prostate cancer therapy segment is expected to hold the highest market share of 38.6% in 2025.
| By Drug Class | Value Share (2025) |
|---|---|
| Hormonal Prostate Cancer Therapy | 38.6% |
Hormonal prostate cancer therapy dominates the market for prostate cancer, basically because of long-standing efficacy of this treatment especially in advanced or metastatic states of the disease.
This can also be termed as androgen deprivation therapy, meaning it lowers the levels of these male hormones by either blocking the production of such hormones or destroying their ability to cause any change. This therapy is commonly the first line of treatment in advanced prostate cancer and is essentially the cornerstone for both early and late-stage management.
The dominance of hormonal therapy is fueled by the universal acceptability of use in the therapeutic area of castration-resistant prostate cancer (CRPC) and metastatic prostate cancer (mPC). Demonstrated as well as established along with clinical guidelines, hormonal therapies are prescribed worldwide.
Furthermore, recent developments in hormone therapy have proven next-generation androgen receptor inhibitors like abiraterone and enzalutamide to revolutionize survival. Hence, hormonal prostate cancer therapy has been in the largest market share and remains integral in the treatment regimen for prostate cancer.
| By Distribution Channel | Value Share (2025) |
|---|---|
| Hospital Pharmacies | 44.2% |
Hospitals are often the initial or the main healthcare facilities for a prostate cancer patient, especially during the later stages when chemotherapy, immunotherapy, and targeted therapy are initiated. Hospital pharmacies are, therefore, called upon to provide these treatments, storing and preparing drugs under appropriate conditions. They then ensure drug administration under strict professional surveillance.
Besides providing prescribed drugs, hospital pharmacies also manage oncology-specific drugs and offer comprehensive patient care services, which are quite crucial for prostate cancer patients. The multifaceted treatment process often involves collaboration among such luminaries as oncologists, urologists, and even pharmacists, to ensure a smooth and well-tailored treatment regimen.
High volume of cancer treatments and specialized care benefit hospital pharmacies in terms of dominating the distribution channel for prostate cancer therapies. Besides, most patients prefer receiving their treatment in a hospital setting since they can be offered specialized healthcare services. This is one reason why hospital pharmacies are still dominating the market.
Key strategies include product differentiation via innovative formulation methods, as well as strategic partnerships with healthcare providers for distribution. Another strategic thrust for these companies is the proactive identification of potential partners who can strengthen their product line in consideration and enhance their global reach.
Recent Developments in the Prostate Cancer Industry
The global prostate cancer market is projected to witness CAGR of 8.5% between 2025 and 2035.
India is set to record the highest CAGR of 7.9% in the assessment period.
The key players operating in the global prostate cancer market include Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Ipsen Pharma, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Exelixis, Inc. and Clovis Oncology, Inc.
In terms of drug class, the industry is divided into- hormonal prostate cancer therapy (luteinizing hormone-releasing hormone (LHRH) antagonists, luteinizing hormone-releasing hormone (LHRH) agonists, anti-androgen), prostate cancer chemotherapy (taxotere and jevtana), prostate cancer immunotherapy (provenge), prostate cancer targeted therapy (xofigo) and other prostate cancer.
In terms of distribution channel, the industry is segregated into- hospital pharmacies, drug stores & retail pharmacies and online pharmacies.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
Endometrial Ablation Market Analysis - Size, Share & Forecast 2025 to 2035
Endotracheal Tube Market - Growth & Demand Outlook 2025 to 2035
Electrophoresis Market Trends - Growth, Demand & Forecast 2025 to 2035
Electrosurgery Devices Market Overview - Trends & Growth Forecast 2025 to 2035
ePharmacy Market Overview – Trends, Demand & Forecast 2025 to 2035
Epilepsy Monitoring Devices Market Growth - Trends & Forecast 2025 to 2035
Prostate Cancer Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
